The European Vaccine Initiative's (EVI) work is rooted in our commitment to the UN Millennium Development Goals. Our vision is 'a world free of the intolerable burden of diseases of poverty and emerging infectious diseases within the coming decades'.
Our objectives seek to deliver this vision. We fund studies to bridge the gap between promising vaccine candidates and late-stage clinical trials. More broadly, we foster an environment in which potential vaccines can be brought to clinical trials and made accessible to low income populations. In all this we collaborate with multiple stakeholders, to whom we offer a forum and focal point.
EVI was established by Stockholm University and Heidelberg University, in March 2011 four new institutions were registered in the European Economic Interest Grouping, which is the legal identity of EVI, and in 2014 Institut Pasteur joined the EEIG:
Biomedical Primate Research Centre (BPRC) in The Netherlands
Jenner Vaccine Foundation, University of Oxford
National Institute for Public Health and the Environment (Intravacc)
Royal College of Surgeons in Ireland (RCSI)
Institut Pasteur (IP)